Skip to main content
Equibles
OSRH logo

OSRH · OSR Health, Inc. · Metrics

Track OSRH — free

Use OSRH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OSRH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.17 +0.05 (+43.78%) At close · Aug 26
Rebalance outlook locked
Customer concentration — top 3 customers 95% of revenue

3 customers — 95% of revenue

“Three main customers of RMC have in recent years represented approximately 95% of RMC's total sales.”
View the 10-K filed Mar 31, 2026
Market Cap
$4.09M
Shares
35.12M
Volume · Aug 26 4.48M Avg daily vol (3M) 9.94M

OSRH metrics

62 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.17
Market cap
$4.09M

Price action

23 metrics
Price change (1W)
-55.1%
Price change (30D)
—
Price change (3M)
-65.4%
Price change (6M)
-62.0%
Price change (YTD)
-70.3%
Price change (1Y)
-82.9%
Trailing year
Price change (5Y)
—
52-week high
$0.98
52-week low
$0.12
Change from 52-week high
-82.9%
Change from 52-week low
+43.8%
Annualized volatility
176.7%
Annualized volatility (3M)
252.7%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.6
RSI (14D)
37.1
Price vs SMA 50
-55.2%
Price vs SMA 200
-67.2%
Avg volume (3M)
9.94M
Relative volume
0.5
Average dollar volume
$4.96M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
35.12M

Valuation

12 metrics
P / E (TTM)
538.0
Trailing earnings · reciprocal yield 0.2%
PEG ratio
—
EV / revenue
1.7×
reciprocal yield 57.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
2.3×
reciprocal yield 44.2%
P / book
0.0
reciprocal yield 3,053.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-364.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
35.3%
Operating margin
-933.7%
Trailing 12 months
Net margin
-824.4%
Gross profit (TTM)
$638,323
Operating profit (TTM)
−$16.89M
Net income (TTM)
−$14.91M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$4.78

Growth

11 metrics
Revenue growth YoY
-72.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.81M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+214.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-11.9%
Return on assets
-8.9%
Debt / equity
0.0
Current ratio
0.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-34.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$955,553
Latest balance sheet
Cash & equivalents
$1.50M
Total assets
$166.62M
Total debt
$544,050

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.20M
Capital expenditures (TTM)
—
R&D (TTM)
$382,549
SG&A (TTM)
$17.53M
Stock compensation (TTM)
—
R&D / revenue
21.1%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
30
13F filer change QoQ
+3
Institutional ownership
11.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
1.0%
Private-fund adviser ownership
0.4%
Active holders' share change QoQ
+178.7%
Holder tenure
1.8
Price vs estimated holder cost
-50.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.3%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1840425 CUSIP 68840D102 Visit website